Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis
- 15 Downloads
Insulin resistance contributes to the pathogenesis of both polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD). The main aim of the present study was the evaluation of non-invasive indices of hepatic steatosis and fibrosis in PCOS women with or without metabolic syndrome (MetS).
In this cross-sectional study, three non-invasive indices for hepatic steatosis [NAFLD liver fat score, lipid accumulation product (LAP) and hepatic steatosis index (HIS)] and four for fibrosis [FIB-4, aspartate aminotransferase (AST)-to-Platelet Ratio Index (APRI), body mass index (BMI)-Age-Alanine aminotransferase (ALT)-Triglycerides (BAAT) and BMI AST/ALT Ratio Diabetes (BARD)] were calculated in 314 PCOS women (77 with, 237 without MetS) and 78 controls.
All steatosis indices were significantly higher in the PCOS than the control group (NAFLD liver fat score: −0.139±0.117 vs. −0.976±0.159, p<0.001; LAP: 43.3±1.9 vs. 34.7±3.1, p = 0.036; HIS: 44.6±0.5 vs. 42.1±0.8, p = 0.016). FIB-4 and BAAT [fibrosis stage (F)2-4] were higher in the PCOS group (0.480±0.020 vs. 0.400±0.013, p<0.001; and 15.6% vs. 5.1%, respectively), whereas APRI and BARD were not. All steatosis indices were significantly higher in PCOS women with than without MetS (NAFLD liver fat score: 1.874±0.258 vs. −0.793±0.099, p < 0.001; LAP: 76.8±4.9 vs. 33.4 ± 1.4, p < 0.001; and HIS: 49.8±1 vs. 43±0.5, p<0.001). Of the fibrosis indices, only BAAT (F2-4: 50.6% vs. 4.2%) was higher in PCOS women with MetS.
Non-invasive indices of hepatic steatosis were significantly higher in PCOS, especially in the presence of MetS, whereas indices of hepatic fibrosis yielded controversial results. Further studies are warranted to evaluate the long-term outcomes of hepatic steatosis and fibrosis indices in PCOS women.
Key WordsAPRI FIB-4 Hepatic steatosis index Insulin resistance Lipid accumulation product Metabolic syndrome NAFLD liver fat score Steatosis
- 10.Chalasani N, Younossi Z, Lavine JE, et al, 2012 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023.CrossRefGoogle Scholar
- 27.Jones H, Sprung VS, Pugh CJ, et al, 2012 Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 97: 3709–3716.CrossRefGoogle Scholar